http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 06:19:22 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Spyre+%28SYRE%29+PT+Lowered+to+%24116+at+Baird/26984271.html Baird analyst Colleen Kusy lowered the price target on Spyre (NASDAQ: SYRE) to $116.00 (from $120.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Spyre+%28SYRE%29+PT+Lowered+to+%24116+at+Baird/26984271.html Thu, 27 Aug 2026 06:19:22 -0400 SYRE http://www.streetinsider.com/Analyst+Comments/Guggenheim+Reiterates+Buy+Rating+on+Spyre+%28SYRE%29/26983471.html <p>Guggenheim analyst Yatin Suneja reiterated a Buy rating and $130.00 price target on Spyre (NASDAQ: SYRE)</p><p>The analyst comments: “Yesterday, Spyre announced topline results for the Phase II SKYWAY-RA program. In short, SPY072/TL1A showed profound evidence of target engagement and stat-sig and/or numerically greater efficacy improvement over placebo (i.e., ACR20/50/70 and ΔDAS28-CRP) across both doses in both TNF-naive & TNF-exp RA patients. Safety was consistent within the known TL1A profile to-date, with no drug-induced SAEs. However, the magnitude of effect hasn't met SYRE's internal bar to justify prioritizing SPY072 monotherapy development, and thus, the company will not advance the RA program http://www.streetinsider.com/Analyst+Comments/Guggenheim+Reiterates+Buy+Rating+on+Spyre+%28SYRE%29/26983471.html Thu, 27 Aug 2026 02:20:08 -0400 SYRE http://www.streetinsider.com/Analyst+Comments/+Spyre+%28SYRE%29+Reiterated+at+Buy+by+Stifel+on+Topline+Results+From+RA+PoC+Sub-Study/26977312.html <p>Stifel analyst Alex Thompson reiterated a Buy rating and $123.00 price target on Spyre (NASDAQ: SYRE).</p><p>The analyst commented, "SYRE announced topline results from the RA PoC sub-study, which while hitting stats on some endpoints/doses, did not achieve a competitive effect size (<1pt delta on DAS-28CRP) to support monotherapy development (safety in-line). Additional PoC datasets in axSpA and PsA are on track for 4Q26. Bottom line, we see broader TL1A indication expansion as orthogonal to our core UC combo thesis for SYRE--Ph2 data on track for next year and still representative of the majority of today's current valuation. While we expect http://www.streetinsider.com/Analyst+Comments/+Spyre+%28SYRE%29+Reiterated+at+Buy+by+Stifel+on+Topline+Results+From+RA+PoC+Sub-Study/26977312.html Wed, 26 Aug 2026 07:28:52 -0400 SYRE http://www.streetinsider.com/Hot+List/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html (Updated - August 25, 2026 4:49 PM EDT) <p><strong>After-Hours Movers</strong>:</p><p><strong>Intuit (NASDAQ: INTU)</strong></p><p>Intuit shares fell 9% after hours as a downbeat full-year forward guidance disappointed investors. The real pressure stemmed from conservative fiscal year 2027 guidance, where Intuit projected full-year EPS of $22.88–$23.12 (missing Wall Street's $27.30 expectation) and revenue of $23.3–$23.5 billion (trailing the $23.74 billion consensus), driven by slower-than-expected TurboTax growth and ongoing platform restructuring.</p><p><strong>Semtech (NASDAQ: SMTC)</strong></p><p>Semtech shares gained 3% following a strong beat-and-raise Q2 performance. The semiconductor supplier delivered adjusted EPS of $0.71 on revenue of $341.9 million, easily topping analyst targets driven by surging 64% growth in its http://www.streetinsider.com/Hot+List/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html Tue, 25 Aug 2026 16:49:08 -0400 INTU NCNO SMTC SYRE ZM http://www.streetinsider.com/Hot+List/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html (Updated - August 25, 2026 4:49 PM EDT) <p><strong>After-Hours Movers</strong>:</p><p><strong>Intuit (NASDAQ: INTU)</strong></p><p>Intuit shares fell 9% after hours as a downbeat full-year forward guidance disappointed investors. The real pressure stemmed from conservative fiscal year 2027 guidance, where Intuit projected full-year EPS of $22.88–$23.12 (missing Wall Street's $27.30 expectation) and revenue of $23.3–$23.5 billion (trailing the $23.74 billion consensus), driven by slower-than-expected TurboTax growth and ongoing platform restructuring.</p><p><strong>Semtech (NASDAQ: SMTC)</strong></p><p>Semtech shares gained 3% following a strong beat-and-raise Q2 performance. The semiconductor supplier delivered adjusted EPS of $0.71 on revenue of $341.9 million, easily topping analyst targets driven by surging 64% growth in its http://www.streetinsider.com/Hot+List/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html Tue, 25 Aug 2026 16:49:08 -0400 INTU NCNO SMTC SYRE ZM http://www.streetinsider.com/Hot+List/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html (Updated - August 25, 2026 4:49 PM EDT) <p><strong>After-Hours Movers</strong>:</p><p><strong>Intuit (NASDAQ: INTU)</strong></p><p>Intuit shares fell 9% after hours as a downbeat full-year forward guidance disappointed investors. The real pressure stemmed from conservative fiscal year 2027 guidance, where Intuit projected full-year EPS of $22.88–$23.12 (missing Wall Street's $27.30 expectation) and revenue of $23.3–$23.5 billion (trailing the $23.74 billion consensus), driven by slower-than-expected TurboTax growth and ongoing platform restructuring.</p><p><strong>Semtech (NASDAQ: SMTC)</strong></p><p>Semtech shares gained 3% following a strong beat-and-raise Q2 performance. The semiconductor supplier delivered adjusted EPS of $0.71 on revenue of $341.9 million, easily topping analyst targets driven by surging 64% growth in its http://www.streetinsider.com/Hot+List/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html Tue, 25 Aug 2026 16:49:08 -0400 INTU NCNO SMTC SYRE ZM http://www.streetinsider.com/Hot+List/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html (Updated - August 25, 2026 4:49 PM EDT) <p><strong>After-Hours Movers</strong>:</p><p><strong>Intuit (NASDAQ: INTU)</strong></p><p>Intuit shares fell 9% after hours as a downbeat full-year forward guidance disappointed investors. The real pressure stemmed from conservative fiscal year 2027 guidance, where Intuit projected full-year EPS of $22.88–$23.12 (missing Wall Street's $27.30 expectation) and revenue of $23.3–$23.5 billion (trailing the $23.74 billion consensus), driven by slower-than-expected TurboTax growth and ongoing platform restructuring.</p><p><strong>Semtech (NASDAQ: SMTC)</strong></p><p>Semtech shares gained 3% following a strong beat-and-raise Q2 performance. The semiconductor supplier delivered adjusted EPS of $0.71 on revenue of $341.9 million, easily topping analyst targets driven by surging 64% growth in its http://www.streetinsider.com/Hot+List/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html Tue, 25 Aug 2026 16:49:08 -0400 INTU NCNO SMTC SYRE ZM http://www.streetinsider.com/Hot+List/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html (Updated - August 25, 2026 4:49 PM EDT) <p><strong>After-Hours Movers</strong>:</p><p><strong>Intuit (NASDAQ: INTU)</strong></p><p>Intuit shares fell 9% after hours as a downbeat full-year forward guidance disappointed investors. The real pressure stemmed from conservative fiscal year 2027 guidance, where Intuit projected full-year EPS of $22.88–$23.12 (missing Wall Street's $27.30 expectation) and revenue of $23.3–$23.5 billion (trailing the $23.74 billion consensus), driven by slower-than-expected TurboTax growth and ongoing platform restructuring.</p><p><strong>Semtech (NASDAQ: SMTC)</strong></p><p>Semtech shares gained 3% following a strong beat-and-raise Q2 performance. The semiconductor supplier delivered adjusted EPS of $0.71 on revenue of $341.9 million, easily topping analyst targets driven by surging 64% growth in its http://www.streetinsider.com/Hot+List/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html Tue, 25 Aug 2026 16:49:08 -0400 INTU NCNO SMTC SYRE ZM http://www.streetinsider.com/Special+Reports/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html (Updated - August 25, 2026 4:49 PM EDT) <p><strong>After-Hours Movers</strong>:</p><p><strong>Intuit (NASDAQ: INTU)</strong></p><p>Intuit shares fell 9% after hours as a downbeat full-year forward guidance disappointed investors. The real pressure stemmed from conservative fiscal year 2027 guidance, where Intuit projected full-year EPS of $22.88–$23.12 (missing Wall Street's $27.30 expectation) and revenue of $23.3–$23.5 billion (trailing the $23.74 billion consensus), driven by slower-than-expected TurboTax growth and ongoing platform restructuring.</p><p><strong>Semtech (NASDAQ: SMTC)</strong></p><p>Semtech shares gained 3% following a strong beat-and-raise Q2 performance. The semiconductor supplier delivered adjusted EPS of $0.71 on revenue of $341.9 million, easily topping analyst targets driven by surging 64% growth in its http://www.streetinsider.com/Special+Reports/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html Tue, 25 Aug 2026 16:49:08 -0400 INTU NCNO SMTC SYRE ZM http://www.streetinsider.com/Special+Reports/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html (Updated - August 25, 2026 4:49 PM EDT) <p><strong>After-Hours Movers</strong>:</p><p><strong>Intuit (NASDAQ: INTU)</strong></p><p>Intuit shares fell 9% after hours as a downbeat full-year forward guidance disappointed investors. The real pressure stemmed from conservative fiscal year 2027 guidance, where Intuit projected full-year EPS of $22.88–$23.12 (missing Wall Street's $27.30 expectation) and revenue of $23.3–$23.5 billion (trailing the $23.74 billion consensus), driven by slower-than-expected TurboTax growth and ongoing platform restructuring.</p><p><strong>Semtech (NASDAQ: SMTC)</strong></p><p>Semtech shares gained 3% following a strong beat-and-raise Q2 performance. The semiconductor supplier delivered adjusted EPS of $0.71 on revenue of $341.9 million, easily topping analyst targets driven by surging 64% growth in its http://www.streetinsider.com/Special+Reports/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html Tue, 25 Aug 2026 16:49:08 -0400 INTU NCNO SMTC SYRE ZM http://www.streetinsider.com/Special+Reports/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html (Updated - August 25, 2026 4:49 PM EDT) <p><strong>After-Hours Movers</strong>:</p><p><strong>Intuit (NASDAQ: INTU)</strong></p><p>Intuit shares fell 9% after hours as a downbeat full-year forward guidance disappointed investors. The real pressure stemmed from conservative fiscal year 2027 guidance, where Intuit projected full-year EPS of $22.88–$23.12 (missing Wall Street's $27.30 expectation) and revenue of $23.3–$23.5 billion (trailing the $23.74 billion consensus), driven by slower-than-expected TurboTax growth and ongoing platform restructuring.</p><p><strong>Semtech (NASDAQ: SMTC)</strong></p><p>Semtech shares gained 3% following a strong beat-and-raise Q2 performance. The semiconductor supplier delivered adjusted EPS of $0.71 on revenue of $341.9 million, easily topping analyst targets driven by surging 64% growth in its http://www.streetinsider.com/Special+Reports/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html Tue, 25 Aug 2026 16:49:08 -0400 INTU NCNO SMTC SYRE ZM http://www.streetinsider.com/Special+Reports/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html (Updated - August 25, 2026 4:49 PM EDT) <p><strong>After-Hours Movers</strong>:</p><p><strong>Intuit (NASDAQ: INTU)</strong></p><p>Intuit shares fell 9% after hours as a downbeat full-year forward guidance disappointed investors. The real pressure stemmed from conservative fiscal year 2027 guidance, where Intuit projected full-year EPS of $22.88–$23.12 (missing Wall Street's $27.30 expectation) and revenue of $23.3–$23.5 billion (trailing the $23.74 billion consensus), driven by slower-than-expected TurboTax growth and ongoing platform restructuring.</p><p><strong>Semtech (NASDAQ: SMTC)</strong></p><p>Semtech shares gained 3% following a strong beat-and-raise Q2 performance. The semiconductor supplier delivered adjusted EPS of $0.71 on revenue of $341.9 million, easily topping analyst targets driven by surging 64% growth in its http://www.streetinsider.com/Special+Reports/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html Tue, 25 Aug 2026 16:49:08 -0400 INTU NCNO SMTC SYRE ZM http://www.streetinsider.com/Special+Reports/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html (Updated - August 25, 2026 4:49 PM EDT) <p><strong>After-Hours Movers</strong>:</p><p><strong>Intuit (NASDAQ: INTU)</strong></p><p>Intuit shares fell 9% after hours as a downbeat full-year forward guidance disappointed investors. The real pressure stemmed from conservative fiscal year 2027 guidance, where Intuit projected full-year EPS of $22.88–$23.12 (missing Wall Street's $27.30 expectation) and revenue of $23.3–$23.5 billion (trailing the $23.74 billion consensus), driven by slower-than-expected TurboTax growth and ongoing platform restructuring.</p><p><strong>Semtech (NASDAQ: SMTC)</strong></p><p>Semtech shares gained 3% following a strong beat-and-raise Q2 performance. The semiconductor supplier delivered adjusted EPS of $0.71 on revenue of $341.9 million, easily topping analyst targets driven by surging 64% growth in its http://www.streetinsider.com/Special+Reports/After-Hours+Movers%3A+INTU%2C+SMTC%2C+SYRE%2C+ZM%2C+NCNO/26975295.html Tue, 25 Aug 2026 16:49:08 -0400 INTU NCNO SMTC SYRE ZM http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spyre+Therapeutics%2C+Inc.++For%3A+Aug+25/26974650.html si-local-file:///var/storage/secattach/20260825/26974650.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spyre+Therapeutics%2C+Inc.++For%3A+Aug+25/26974650.html Tue, 25 Aug 2026 16:05:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spyre+Therapeutics%2C+Inc.++For%3A+Aug+25/26974650.html si-local-file:///var/storage/secattach/20260825/26974650.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spyre+Therapeutics%2C+Inc.++For%3A+Aug+25/26974650.html Tue, 25 Aug 2026 16:05:00 -0400 O.25515888 SYRE http://www.streetinsider.com/FDA/Spyre+RA+drug+trial+misses+internal+bar+despite+some+efficacy/26974576.html <p>Spyre Therapeutics (NASDAQ: SYRE) announced topline results from the rheumatoid arthritis sub-study of its Phase 2 SKYWAY trial evaluating SPY072, a TL1A inhibitor, saying the results did not meet the company's internal threshold to advance SPY072 as a monotherapy in rheumatoid arthritis.</p> <p>Both doses of SPY072 showed statistically significant benefits versus placebo on one or more endpoints at Week 12. The low dose met the primary endpoint, a change from baseline in DAS28-CRP, with a score of -1.9 compared to -1.3 for placebo. The high dose showed a nominally significant ACR20 response rate of 63% versus 43% for placebo, and the http://www.streetinsider.com/FDA/Spyre+RA+drug+trial+misses+internal+bar+despite+some+efficacy/26974576.html Tue, 25 Aug 2026 16:01:16 -0400 SYRE http://www.streetinsider.com/Press+Releases/Spyre+Therapeutics+Announces+Topline+Results+from+the+Rheumatoid+Arthritis+Sub-study+of+the+SKYWAY+Phase+2+Trial+of+SPY072/26974571.html <p align="center"><em>Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)</em></p> <p align="center"><em>SPY072 was well tolerated with rates of adverse events comparable to placebo</em></p> <p align="center"><em>Magnitude of effect did not meet the Company’s target to prioritize monotherapy development of SPY072 in rheumatoid arthritis (RA); results support the broad potential of Spyre’s TL1A antibodies in autoimmune disease and as combination components</em></p> <p align="center"><em>Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for http://www.streetinsider.com/Press+Releases/Spyre+Therapeutics+Announces+Topline+Results+from+the+Rheumatoid+Arthritis+Sub-study+of+the+SKYWAY+Phase+2+Trial+of+SPY072/26974571.html Tue, 25 Aug 2026 16:01:00 -0400 SYRE http://www.streetinsider.com/Globe+Newswire/Spyre+Therapeutics+Announces+Topline+Results+from+the+Rheumatoid+Arthritis+Sub-study+of+the+SKYWAY+Phase+2+Trial+of+SPY072/26974571.html <p align="center"><em>Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)</em></p> <p align="center"><em>SPY072 was well tolerated with rates of adverse events comparable to placebo</em></p> <p align="center"><em>Magnitude of effect did not meet the Company’s target to prioritize monotherapy development of SPY072 in rheumatoid arthritis (RA); results support the broad potential of Spyre’s TL1A antibodies in autoimmune disease and as combination components</em></p> <p align="center"><em>Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for http://www.streetinsider.com/Globe+Newswire/Spyre+Therapeutics+Announces+Topline+Results+from+the+Rheumatoid+Arthritis+Sub-study+of+the+SKYWAY+Phase+2+Trial+of+SPY072/26974571.html Tue, 25 Aug 2026 16:01:00 -0400 SYRE http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Spyre+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26932871.html si-local-file:///var/storage/secattach/20260814/26932871.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Spyre+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26932871.html Fri, 14 Aug 2026 17:24:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Spyre+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26932871.html si-local-file:///var/storage/secattach/20260814/26932871.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Spyre+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26932871.html Fri, 14 Aug 2026 17:24:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Spyre+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26924967.html si-local-file:///var/storage/secattach/20260814/26924967.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Spyre+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26924967.html Fri, 14 Aug 2026 08:10:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Spyre+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26924967.html si-local-file:///var/storage/secattach/20260814/26924967.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Spyre+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+RTW+INVESTMENTS%2C+LP/26924967.html Fri, 14 Aug 2026 08:10:00 -0400 O.25515888 SYRE http://www.streetinsider.com/Analyst+PT+Change/Spyre+%28SYRE%29+PT+Raised+to+%24140+at+Jones+Trading/26910244.html Jones Trading analyst Debanjana Chatterjee raised the price target on Spyre (NASDAQ: SYRE) to $140.00 (from $104.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Spyre+%28SYRE%29+PT+Raised+to+%24140+at+Jones+Trading/26910244.html Wed, 12 Aug 2026 09:45:50 -0400 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+Aug+07++Filed+by%3A+Albers+Jeffrey+W./26899743.html si-local-file:///var/storage/secattach/20260810/26899743.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+Aug+07++Filed+by%3A+Albers+Jeffrey+W./26899743.html Mon, 10 Aug 2026 21:32:00 -0400 O.25515888 SYRE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+Aug+07++Filed+by%3A+Albers+Jeffrey+W./26899743.html si-local-file:///var/storage/secattach/20260810/26899743.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spyre+Therapeutics%2C+Inc.++For%3A+Aug+07++Filed+by%3A+Albers+Jeffrey+W./26899743.html Mon, 10 Aug 2026 21:32:00 -0400 O.25515888 SYRE